Patent ID: 9737604
Date: 2017-08-22
CPC Classifications: A61K,A61P,C07K,C12N,C12Y

Claim:
1. A composition comprising a Cas9 protein and a cationic lipid, wherein the Cas9 protein is associated with a guide RNA (gRNA), and the composition is capable of delivering the Cas9 protein associated with the gRNA to the nucleus of a cell, wherein the Cas9 protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 44, or the Cas9 protein is a nuclease-inactivated Cas9 (dCas9) that comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 45 and comprises a D10A and/or a 11840A substitution as compared to the amino acid sequence of wild type Cas9; wherein the Cas9 protein is associated with a supercharged protein having a net negative charge of at least −5 at pH 7.4, and exhibiting a charge:molecular weight ratio of greater than 0.8, wherein the association has a net negative charge at pH 7.4; and the cationic lipid is Lipofectamine® 2000 or Lipofectamine® RNAiMAX.